Carsten Nieder1,2, Dirk De Ruysscher3, Laurie E Gaspar4, Matthias Guckenberger5, Minesh P Mehta6, Patrick Cheung7, Arjun Sahgal7. 1. Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway. carsten.nieder@nlsh.no. 2. Institute of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway. carsten.nieder@nlsh.no. 3. Department of Radiation Oncology, MAASTRO Clinic, Maastricht, The Netherlands. 4. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, USA. 5. Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland. 6. Department of Radiation Oncology, Miami Cancer Institute, Miami, FL, USA. 7. Department of Radiation Oncology, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Canada.
Abstract
BACKGROUND: Practice guidelines have been developed for early-stage and locally advanced non-small cell lung cancer (NSCLC). However, many common clinical scenarios still require individualized decision making. This is true for locoregional relapse after initial stereotactic radiotherapy (stereotactic body radiation therapy or stereotactic ablative radiotherapy; SBRT or SABR), an increasingly utilized curative treatment option for stage I NSCLC. METHODS: A consortium of expert radiation oncologists was established with the aim of providing treatment recommendations. In this scenario, a case was distributed to six radiation oncologists who provided their institutions' treatment recommendations. In this case, a patient developed local and mediastinal relapse after SABR (45 Gy, 3 fractions), comparable to the tumor burden in de novo stage IIIA NSCLC. Treatment recommendations were tabulated and a consensus conclusion was developed. RESULTS: Three institutions recommended evaluation for surgery. If the patient was not a surgical candidate, and/or refused surgery, definitive chemoradiation was recommended, including retreating the primary to full dose. European participants were more in favor of a non-surgical approach. None of the participants were reluctant to prescribe reirradiation, but two institutions prescribed doses lower than 60 Gy. Platinum-based doublets together with intensity-modulated radiotherapy were preferred. CONCLUSION: The institutional recommendations reflect the questions and uncertainties discussed in current stage III guidelines. All institutions agreed that previous SABR is not a contraindication for salvage chemoradiation. In the absence of high-quality prospective trials for recurrent NSCLC, all treatment options recommended in current guidelines for stage III disease can be considered in clinical scenarios such as this.
BACKGROUND: Practice guidelines have been developed for early-stage and locally advanced non-small cell lung cancer (NSCLC). However, many common clinical scenarios still require individualized decision making. This is true for locoregional relapse after initial stereotactic radiotherapy (stereotactic body radiation therapy or stereotactic ablative radiotherapy; SBRT or SABR), an increasingly utilized curative treatment option for stage I NSCLC. METHODS: A consortium of expert radiation oncologists was established with the aim of providing treatment recommendations. In this scenario, a case was distributed to six radiation oncologists who provided their institutions' treatment recommendations. In this case, a patient developed local and mediastinal relapse after SABR (45 Gy, 3 fractions), comparable to the tumor burden in de novo stage IIIA NSCLC. Treatment recommendations were tabulated and a consensus conclusion was developed. RESULTS: Three institutions recommended evaluation for surgery. If the patient was not a surgical candidate, and/or refused surgery, definitive chemoradiation was recommended, including retreating the primary to full dose. European participants were more in favor of a non-surgical approach. None of the participants were reluctant to prescribe reirradiation, but two institutions prescribed doses lower than 60 Gy. Platinum-based doublets together with intensity-modulated radiotherapy were preferred. CONCLUSION: The institutional recommendations reflect the questions and uncertainties discussed in current stage III guidelines. All institutions agreed that previous SABR is not a contraindication for salvage chemoradiation. In the absence of high-quality prospective trials for recurrent NSCLC, all treatment options recommended in current guidelines for stage III disease can be considered in clinical scenarios such as this.
Authors: Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: George Rodrigues; Hak Choy; Jeffrey Bradley; Kenneth E Rosenzweig; Jeffrey Bogart; Walter J Curran; Elizabeth Gore; Corey Langer; Alexander V Louie; Stephen Lutz; Mitchell Machtay; Varun Puri; Maria Werner-Wasik; Gregory M M Videtic Journal: Pract Radiat Oncol Date: 2015 May-Jun
Authors: Matthew C Ward; Steven C Oh; Yvonne D Pham; Neil M Woody; Gaurav Marwaha; Gregory M M Videtic; Kevin L Stephans Journal: J Thorac Oncol Date: 2016-05-17 Impact factor: 15.609
Authors: Cary Oberije; Dirk De Ruysscher; Ruud Houben; Michel van de Heuvel; Wilma Uyterlinde; Joseph O Deasy; Jose Belderbos; Anne-Marie C Dingemans; Andreas Rimner; Shaun Din; Philippe Lambin Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-30 Impact factor: 7.038
Authors: Susanne Stera; Panagiotis Balermpas; Mark K H Chan; Stefan Huttenlocher; Stefan Wurster; Christian Keller; Detlef Imhoff; Dirk Rades; Jürgen Dunst; Claus Rödel; Guido Hildebrandt; Oliver Blanck Journal: Strahlenther Onkol Date: 2017-09-05 Impact factor: 3.621
Authors: Rene Baumann; Mark K H Chan; Florian Pyschny; Susanne Stera; Bettina Malzkuhn; Stefan Wurster; Stefan Huttenlocher; Marcella Szücs; Detlef Imhoff; Christian Keller; Panagiotis Balermpas; Dirk Rades; Claus Rödel; Jürgen Dunst; Guido Hildebrandt; Oliver Blanck Journal: Front Oncol Date: 2018-05-17 Impact factor: 6.244